Abstract
A series of hybrids of 3-hydroxy-indolin-2-one and 2,3-dihydroquinolin-4(1H) -one were synthesized and their anti-proliferative activities against two human cancer cell lines were initially evaluated. Compound 7g was selected for further study and demonstrated moderate anti-proliferative activities against four human cancer cell lines. Meanwhile, 7g had inhibitory effects on the growth of SGC-7901 cells in dosage-and time-dependent manners and the cancer cells appeared morphological changes. Moreover, 7g was more effective in the inhibition of xenografted tumor in vivo growth and mice treated with 7g showed more weight gain than 5-FU-treated mice over the treatment period, suggesting a lower toxic effect than 5-FU. After treatment with 7g, the tumor showed typical morphological changes as evaluated by H&E staining.
Keywords: 3-Hydroxy-indolin-2-one, 2, 3-Dihydroquinolin-4(1H)-one, anticancer, hybrid, isatin, synthesis.
Letters in Drug Design & Discovery
Title:Synthesis, in Vitro and in Vivo Anticancer Activity of Hybrids of 3- Hydroxy-indolin-2-one and 2,3-Dihydroquinolin-4(1H)-one
Volume: 12 Issue: 2
Author(s): Lei Zhang, Jing Wang, Wen-Yun Li, Juan Xia, Jing Gao and Qi-Zheng Yao
Affiliation:
Keywords: 3-Hydroxy-indolin-2-one, 2, 3-Dihydroquinolin-4(1H)-one, anticancer, hybrid, isatin, synthesis.
Abstract: A series of hybrids of 3-hydroxy-indolin-2-one and 2,3-dihydroquinolin-4(1H) -one were synthesized and their anti-proliferative activities against two human cancer cell lines were initially evaluated. Compound 7g was selected for further study and demonstrated moderate anti-proliferative activities against four human cancer cell lines. Meanwhile, 7g had inhibitory effects on the growth of SGC-7901 cells in dosage-and time-dependent manners and the cancer cells appeared morphological changes. Moreover, 7g was more effective in the inhibition of xenografted tumor in vivo growth and mice treated with 7g showed more weight gain than 5-FU-treated mice over the treatment period, suggesting a lower toxic effect than 5-FU. After treatment with 7g, the tumor showed typical morphological changes as evaluated by H&E staining.
Export Options
About this article
Cite this article as:
Zhang Lei, Wang Jing, Li Wen-Yun, Xia Juan, Gao Jing and Yao Qi-Zheng, Synthesis, in Vitro and in Vivo Anticancer Activity of Hybrids of 3- Hydroxy-indolin-2-one and 2,3-Dihydroquinolin-4(1H)-one, Letters in Drug Design & Discovery 2015; 12 (2) . https://dx.doi.org/10.2174/1570180811666140909010017
DOI https://dx.doi.org/10.2174/1570180811666140909010017 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Synthesis and Medicinal Applications of Compounds Derived from Phthalimide
Current Organic Synthesis Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma
Current Topics in Medicinal Chemistry Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors
Current Topics in Medicinal Chemistry Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Nanomedicine and its Application in Treatment of Microglia-mediated Neuroinflammation
Current Medicinal Chemistry Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Editorial [Hot topic: Bisphosphonates and Bone Diseases: Past, Present and Future (Guest Editor: Dominique HEYMANN)]
Current Pharmaceutical Design Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Current Medicinal Chemistry C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors
Current Cancer Drug Targets The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer
Current Drug Targets Structure of Multidrug-Resistance Proteins of the ATP-Binding Cassette (ABC) Superfamily
Current Medicinal Chemistry - Anti-Cancer Agents Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Taxotere Chemosensitivity Evaluation in Rat Breast Tumor by Multimodal Imaging: Quantitative Measurement by Fusion of MRI, PET Imaging with MALDI and Histology
Recent Patents on Medical Imaging New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?
Current Gene Therapy